A Phase 1/2 Study of the Safety Pharmacokinetics and Pharmacodynamics of the Glutaminase Inhibitor CB-839 in Combination with Nivolumab in Patients with Clear Cell Renal Cell Carcinoma and Other Solid Tumors
Brief description of study
The main goal of this Phase I/II study is to evaluate the safety and tolerability of the drug CB-839 (a glutaminase inhibitor) in combination with nivolumab (an anti-PD-1 agent or immunotherapy) in patients with advanced/metastatic cancer (cancer that has spread to other parts of the body). The study is enrolling patients with non-small cell lung cancer (NSCLC) and kidney cancer (renal cell carcinoma, RCC). In laboratory studies, adding CB-389 to nivolumab may overcame resistance to nivolumab.
Clinical Study Identifier: s17-00293
ClinicalTrials.gov Identifier: NCTs17-00293
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.